- Hello, I'm Mariell Jessup, the immediate
Past President of the
American Heart Association.
And I'm here for Science
News at the European Society
of Cardiology's meeting in Barcelona.
There's no question that
the really big news here at
the meeting will be the
paradigm heart failure trial.
This is a large randomized
trial in patients with HEFREF,
heart failure with reduced
dejection fraction.
Using the new and novel agent
LCZ696, it's a single agent
and it was compared in
paradigm heart failure or
paradigm HF to enalapril,
at 10 milligrams BID.
We already know that this
trial was stopped early
because of efficacy.
And the trial was powered
for all-cost mortality.
What we know and what we
learned from the news conference
is this was a trial that
had positive results
across all endpoints.
People are already beginning
to say this drug may
actually change the way we manage HEFREF,
heart failure with reduced
dejection fraction,
for the first time in many many years.
So today was the press conference,
tomorrow is the
presentation of the hotline,
and the paradigm H and
F is the first trial,
I'm very excited to moderate the session,
and we can't wait to spread
the news about a positive
heart failure trial.
I'm Mariell Jessup, for Science News.
